← brief for 2026-08-11 · Slowing decline

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Trial No results yet Not peer reviewed

Key takeaways

This is an early safety and dosing study of a drug called eloralintide in people with reduced kidney function, compared with people whose kidneys work normally. It measures how much of the drug reaches the blood and how long the body takes to clear it. It does not test whether the drug helps kidney disease, and there are no results yet.

Who did this work

Run by Eli Lilly and Company. Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)
Sites: Floridian Clinical Research, LLC · Omega Research Orlando LLC

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-06
https://clinicaltrials.gov/study/NCT07426380